Skip to content

Study · Case report or series · n = 1 · 2015

9 results

Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report.

Palcu P, Dion N, Ste-Marie LG, Goltzman D, Radziunas I, Miller PD, Jamal SA

American journal of kidney diseases : the official journal of the National Kidney Foundation2 Apr 2015Cited by 30 (Europe PMC)

PMID25843705 (opens in a new tab)DOI10.1053/j.ajkd.2015.01.025 (opens in a new tab)PepBankPUB-25843705
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a dialysis patient with low-turnover bone disease, pain resolved within six months of starting teriparatide.

    In plain wordsIn a dialysis patient with low bone turnover, pain resolved within six months of starting teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasePain
    Study

    n = 1

    Outcome group
    Pain · Musculoskeletal
    Studied dose
    20 μg every morning · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Within 6 months of initiating therapy, the patient's pain resolved and he was able to resume work.
    2 context sentences
    Summary · context
    We report on a patient with stage 5 CKD treated with dialysis who presented to our clinic with multiple fractures, including bilateral nondisplaced pelvic fractures resulting in chronic pain and interfering with the patient's ability to work.
    Summary · context
    Bone histomorphometry demonstrated low-turnover bone disease, and he was treated with 20μg of teriparatide (subcutaneous injection) every morning for 24 months.
  2. 02HumanCase report or seriesEfficacy outcome

    In a dialysis patient with low-turnover bone disease, the ability to work returned within six months of starting teriparatide.

    In plain wordsIn a dialysis patient with low bone turnover, the ability to work returned within six months of starting teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseAbility to work
    Study

    n = 1

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    20 μg every morning · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Within 6 months of initiating therapy, the patient's pain resolved and he was able to resume work.
    2 context sentences
    Summary · context
    We report on a patient with stage 5 CKD treated with dialysis who presented to our clinic with multiple fractures, including bilateral nondisplaced pelvic fractures resulting in chronic pain and interfering with the patient's ability to work.
    Summary · context
    Bone histomorphometry demonstrated low-turnover bone disease, and he was treated with 20μg of teriparatide (subcutaneous injection) every morning for 24 months.
  3. 03HumanCase report or seriesSafety outcome

    In a dialysis patient receiving teriparatide, serum calcium remained within reference ranges throughout treatment.

    In plain wordsIn a dialysis patient receiving teriparatide, blood calcium stayed within reference ranges throughout treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableSerum calcium
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 μg every morning · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum calcium and phosphate levels remained within reference ranges throughout his treatment, and he sustained no further fractures.
    2 context sentences
    Summary · context
    We report on a patient with stage 5 CKD treated with dialysis who presented to our clinic with multiple fractures, including bilateral nondisplaced pelvic fractures resulting in chronic pain and interfering with the patient's ability to work.
    Summary · context
    Bone histomorphometry demonstrated low-turnover bone disease, and he was treated with 20μg of teriparatide (subcutaneous injection) every morning for 24 months.
  4. 04HumanCase report or seriesSafety outcome

    In a dialysis patient receiving teriparatide, serum phosphate remained within reference ranges throughout treatment.

    In plain wordsIn a dialysis patient receiving teriparatide, blood phosphate stayed within reference ranges throughout treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableSerum phosphate
    Study

    n = 1

    Outcome group
    Adverse events · Whole body
    Studied dose
    20 μg every morning · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum calcium and phosphate levels remained within reference ranges throughout his treatment, and he sustained no further fractures.
    2 context sentences
    Summary · context
    We report on a patient with stage 5 CKD treated with dialysis who presented to our clinic with multiple fractures, including bilateral nondisplaced pelvic fractures resulting in chronic pain and interfering with the patient's ability to work.
    Summary · context
    Bone histomorphometry demonstrated low-turnover bone disease, and he was treated with 20μg of teriparatide (subcutaneous injection) every morning for 24 months.
  5. 05HumanCase report or seriesEfficacy outcome

    In a dialysis patient with low-turnover bone disease, no further fractures occurred during teriparatide treatment.

    In plain wordsIn a dialysis patient with low bone turnover, no further fractures occurred during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Not applicableFurther fractures
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg every morning · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Serum calcium and phosphate levels remained within reference ranges throughout his treatment, and he sustained no further fractures.
    2 context sentences
    Summary · context
    We report on a patient with stage 5 CKD treated with dialysis who presented to our clinic with multiple fractures, including bilateral nondisplaced pelvic fractures resulting in chronic pain and interfering with the patient's ability to work.
    Summary · context
    Bone histomorphometry demonstrated low-turnover bone disease, and he was treated with 20μg of teriparatide (subcutaneous injection) every morning for 24 months.
  6. 06HumanCase report or seriesEfficacy outcome

    In a dialysis patient with low-turnover bone disease, lumbar spine BMD was maintained during teriparatide treatment.

    In plain wordsIn a dialysis patient with low bone turnover, lower spine bone density stayed stable during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeLumbar spine BMD
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg every morning · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    During 24 months of treatment, bone mineral density was maintained at the lumbar spine, and there was an increase of 4% at the femoral neck and total hip.
    2 context sentences
    Summary · context
    We report on a patient with stage 5 CKD treated with dialysis who presented to our clinic with multiple fractures, including bilateral nondisplaced pelvic fractures resulting in chronic pain and interfering with the patient's ability to work.
    Summary · context
    Bone histomorphometry demonstrated low-turnover bone disease, and he was treated with 20μg of teriparatide (subcutaneous injection) every morning for 24 months.
  7. 07HumanCase report or seriesEfficacy outcome

    In a dialysis patient with low-turnover bone disease, femoral neck BMD increased by 4% during teriparatide treatment.

    In plain wordsIn a dialysis patient with low bone turnover, thighbone neck density increased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral neck BMD
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg every morning · subcutaneous · 24 monthsAs given in this study (human).

    Measurements

    BMD increase
    4%
    femoral neck

    Source sentences

    Summary
    During 24 months of treatment, bone mineral density was maintained at the lumbar spine, and there was an increase of 4% at the femoral neck and total hip.
    2 context sentences
    Summary · context
    We report on a patient with stage 5 CKD treated with dialysis who presented to our clinic with multiple fractures, including bilateral nondisplaced pelvic fractures resulting in chronic pain and interfering with the patient's ability to work.
    Summary · context
    Bone histomorphometry demonstrated low-turnover bone disease, and he was treated with 20μg of teriparatide (subcutaneous injection) every morning for 24 months.
  8. 08HumanCase report or seriesEfficacy outcome

    In a dialysis patient with low-turnover bone disease, total hip BMD increased by 4% during teriparatide treatment.

    In plain wordsIn a dialysis patient with low bone turnover, total hip bone density increased during teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal hip BMD
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg every morning · subcutaneous · 24 monthsAs given in this study (human).

    Measurements

    BMD increase
    4%
    total hip

    Source sentences

    Summary
    During 24 months of treatment, bone mineral density was maintained at the lumbar spine, and there was an increase of 4% at the femoral neck and total hip.
    2 context sentences
    Summary · context
    We report on a patient with stage 5 CKD treated with dialysis who presented to our clinic with multiple fractures, including bilateral nondisplaced pelvic fractures resulting in chronic pain and interfering with the patient's ability to work.
    Summary · context
    Bone histomorphometry demonstrated low-turnover bone disease, and he was treated with 20μg of teriparatide (subcutaneous injection) every morning for 24 months.
  9. 09HumanCase report or seriesEfficacy outcome

    In a dialysis patient with low-turnover bone disease, a second bone biopsy after teriparatide treatment showed improvements in static and dynamic parameters of bone formation.

    In plain wordsIn a dialysis patient with low bone turnover, a second biopsy after teriparatide treatment showed improved static and dynamic bone formation measures.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseStatic and dynamic bone formation parameters
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg every morning · subcutaneous · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    A second transiliac bone biopsy demonstrated improvements in static and dynamic parameters of bone formation.
    2 context sentences
    Summary · context
    We report on a patient with stage 5 CKD treated with dialysis who presented to our clinic with multiple fractures, including bilateral nondisplaced pelvic fractures resulting in chronic pain and interfering with the patient's ability to work.
    Summary · context
    Bone histomorphometry demonstrated low-turnover bone disease, and he was treated with 20μg of teriparatide (subcutaneous injection) every morning for 24 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.